Stay updated on FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial
Sign up to get notified when there's something new on the FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial page.

Latest updates to the FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe study has shifted from focusing on first-line treatment to previously treated patients for both Phase 1 and Phase 2 parts, and the timeline for the study has been updated with new dates. Additionally, the study's title and details have been revised to reflect these changes.SummaryDifference6%
- Check33 days agoNo Change Detected
- Check41 days agoChange DetectedThe webpage now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check48 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check62 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check69 days agoChange DetectedThe website has updated its contact information and added several new sub-investigators, while also removing previous contact details and the principal investigator's name from the visible section.SummaryDifference2%
- Check98 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.1%
Stay in the know with updates to FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial page.